Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 1045

Next Previous
Drug Profile

MK 1045

Alternative Names: CN-201; MK-1045

Latest Information Update: 08 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curon Biopharmaceutical
  • Developer Curon Biopharmaceutical; Merck & Co
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Non-Hodgkin's lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 27 Feb 2026 Phase-I clinical trials in Rheumatoid arthritis in Moldova (Intravitreous) (NCT07363590)
  • 27 Feb 2026 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in Moldova (IV) (NCT07363590)
  • 02 Feb 2026 Merck Sharp & Dohme LLC plans a phase I trial for the Systemic lupus erythematosus (Treatment-experienced) and Rheumatoid arthritis (IV) in Italy, Belgium in February 2026 (NCT07363590) (CTIS-2025-523412-36-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top